Evidence map›Paper›PMID 26622719›Full record

ArticleOncology letters2015

Nuclear medicine techniques in Merkel cell carcinoma: A case report and review of the literature.

Nikolaos Kritikos, Dimitrios Priftakis, Stavros Stavrinides, Stefanos Kleanthous, Eleni Sarafianou

Open access · diamondAbstract read
In one paragraph

Article in Oncology letters, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Merkel Cell Carcinoma Therapeutic Update.Current treatment options in oncology · 2016
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Nikolaos KritikosDepartment of Nuclear Medicine, St. Savvas Anticancer-Oncology Hospital, Athens 11522, Greece.
Dimitrios PriftakisDepartment of Nuclear Medicine, St. Savvas Anticancer-Oncology Hospital, Athens 11522, Greece.
Stavros StavrinidesDepartment of Gastroenterology, St. Savvas Anticancer-Oncology Hospital, Athens 11522, Greece.
Stefanos KleanthousDepartment of Nuclear Medicine, St. Savvas Anticancer-Oncology Hospital, Athens 11522, Greece.
Eleni SarafianouDepartment of Nuclear Medicine, St. Savvas Anticancer-Oncology Hospital, Athens 11522, Greece.
St Savas Hospital · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Merkel cell carcinoma (MCC) is a rare and aggressive type of neuroendocrine cancer of the skin. It predominantly affects the elderly, with a predilection for the sun-exposed skin of the head and neck. Risk factors include immune-suppressing diseases, such as human immunodeficiency virus (HIV), chronic lymphocytic leukemia and multiple myeloma, organ transplantation, and the presence of the newly-identified Merkel cell polyomavirus (MCPyV). Diagnosis is based on pathological findings, primarily the immunohistochemical determination of cytokeratin 20 positivity. By contrast, staging relies on conventional imaging methods, such as ultrasonography, computed tomography (CT) and magnetic resonance imaging, and nuclear medicine techniques, such as sentinel lymph node scintigraphy, somatostatin receptor scintigraphy (SRS), and positron emission tomography (PET)/CT with

Indexed as

merkel cell carcinomanuclear medicinepositron emission tomography-computed tomographysentinel lymph node scintigraphysomatostatin receptor scintigraphy

Identifiers

PMID26622719
PMCPMC4533682
OpenAlexW1941499425

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.